Everist Genomics has launched four companion diagnostics intended to improve early diagnosis, management, and treatment of patients with colorectal cancer.

The tests, which will be available in the US at the end of March, include:

• OncoDefender-MMR, used for prognosis for colorectal cancer patients at all stages of the disease;

• OncoDefender-CRC, designed to identify early-stage colorectal cancer patients likely to benefit from adjuvant chemotherapy;